Pfizer Inc. has revealed the price it is eyeing in the U.S. for its adult COVID-19 vaccine on the commercial market. The Pfizer-BioNTech vaccine would potentially cost between $110 and $130 for a single-dose vial in the U.S., Pfizer’s Angela Lukin said in an analyst and investor call.  That cost will reflect its “cost-effectiveness,” including “increased costs” associated with transitioning from a multi-dose vial to a single-dose and to commercial distribution as well as the value it has “brought to society,” according to Lukin.